EGFR-Homing dsRNA Vector Targeting for Systemic Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting EGFR overexpression, such as small membrane permeable kinase inhibitors and anti-EGFR antibodies, only induce temporary remission and do not cure patients, while systemic administration of non-targeted PolyIC for anti-tumor immunotherapy results in minimal survival benefit with significant toxicity due to inadequate tumor cell dosing and widespread distribution to normal tissues.
Innovation Solution
Development of EGFR-homing vectors comprising double-stranded RNA (dsRNA) molecules with EGFR-binding peptides or polypeptides, specifically targeting EGFR overexpressing cancer cells, combined with immune cells for systemic treatment, utilizing a carrier system of polyethyleneimine (PEI) covalently linked to polyethylene glycol (PEG) and an EGFR-binding peptide like EGF or GE11, to facilitate targeted delivery and activation of cytotoxic cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If non-targeted PolyIC is administered systemically for anti-tumor immunotherapy, then tumor cells may be treated, but the dsRNA scatters through normal tissues causing significant systemic toxicity and minimal survival benefit
Solution Approach 1:
The patent uses an EGFR-targeting antibody as an intermediary carrier to deliver PolyIC specifically to tumor cells expressing EGFR. This antibody-mediated targeting system acts as a bridge between the dsRNA therapeutic and the tumor cells, enabling selective delivery while preventing systemic distribution to normal tissues. The antibody-Fc fusion protein serves as the mediating structure that binds both the targeting antigen (EGFR) and the therapeutic payload (PolyIC).
Solution Approach 2:
The patent segments the delivery system into distinct functional components: an EGFR-targeting antibody portion for selective binding to tumor cells, and a PolyIC payload portion for immunotherapeutic action. This segmentation allows the targeting function and therapeutic function to be separated and optimized independently, with the antibody directing the dsRNA specifically to tumor cells while leaving normal tissues unaffected.
2Reliability
If EGFR-targeted therapies (kinase inhibitors or anti-EGFR antibodies) are used, then receptor activation is prevented, but only temporary or partial remission is achieved without actual cure
Solution Approach 1:
The patent converts the high EGFR expression level, which is typically exploited by targeted therapies to inhibit tumor growth, into a beneficial targeting mechanism. Instead of using EGFR inhibition, the patent uses EGFR as a positive targeting marker to deliver immunotherapeutic dsRNA specifically to tumor cells. The EGFR expression that makes tumors vulnerable to conventional targeted therapy is repurposed to enable selective delivery of curative immunotherapy.
Solution Approach 2:
The patent changes the therapeutic parameter from EGFR inhibition (conventional targeted therapy) to EGFR-mediated delivery (immunotherapy). By altering the mechanism from blocking EGFR function to utilizing EGFR for targeted delivery, the patent transitions from temporary remission to potential cure. The Fc fusion protein parameter change enables extended circulation half-life and enhanced tumor accumulation through EGF receptor-mediated endocytosis.
3Productivity
If conventional EGFR-targeted therapies are administered, then receptor activation is blocked, but the treatment does not actually cure patients
Solution Approach 1:
The patent employs preliminary action by using the EGFR-targeting antibody to pre-direct and concentrate the PolyIC payload specifically at tumor cell locations before the therapeutic action occurs. This preliminary targeting ensures that when PolyIC is delivered, it is already positioned at the correct site (EGFR-positive tumor cells), maximizing treatment effectiveness and enabling curative outcomes rather than just temporary remission.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EGFR-homing vectors effectively eliminate EGFR overexpressing tumors by activating immune cells and inducing a bystander effect, achieving complete tumor eradication with minimal systemic toxicity and improved survival rates in preclinical models, including disseminated tumors.
Implementation Method 1
an EGFR-binding peptide or polypeptide capable of targeting the vector to tumor cells overexpressing EGFR
Implementation Method 2
PolyIC, a synthetic polyinosinic-polycytidylic acid double-stranded RNA, is a known cytotoxic agent... mobilizing the immune system for treatment
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2D
AI summary
An epidermal growth factor receptor (EGFR)-homing vector comprising a doublestranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR.